Literature DB >> 4073092

In vitro activity and disk susceptibility of Timentin: current status.

P C Fuchs, A L Barry, R N Jones.   

Abstract

Mesh：

Substances：

Year:  1985        PMID： 4073092     DOI： 10.1016/0002-9343(85)90125-1

Source DB:  PubMed          Journal:  Am J Med        ISSN： 0002-9343            Impact factor:   4.965


× No keyword cloud information.
  10 in total

1.  Use of a predictor panel for development of a new disk for diffusion tests with cefoperazone-sulbactam.

Authors:  P A Bradford; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

2.  Ticarcillin and ticarcillin-clavulanic acid susceptibility tests: error rates for disk tests with consecutively isolated members of the family Enterobacteriaceae.

Authors:  A L Barry; P C Fuchs; E H Gerlach; D J Hardy; J C McLaughlin; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

3.  Relevant breakpoints for ticarcillin-clavulanic acid should be set primarily with data from ticarcillin-resistant strains.

Authors:  C C Sanders; S J Cavalieri
Journal:  J Clin Microbiol       Date:  1990-04       Impact factor: 5.948

4.  Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model.

Authors:  Brian VanScoy; Rodrigo E Mendes; Anthony M Nicasio; Mariana Castanheira; Catharine C Bulik; Olanrewaju O Okusanya; Sujata M Bhavnani; Alan Forrest; Ronald N Jones; Lawrence V Friedrich; Judith N Steenbergen; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

Review 5.  Enterobacter spp.: pathogens poised to flourish at the turn of the century.

Authors:  W E Sanders; C C Sanders
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

6.  In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentrations of the cefoperazone-sulbactam combination.

Authors:  R N Jones; A L Barry; R R Packer; W W Gregory; C Thornsberry
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

7.  Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests.

Authors:  C C Sanders; J P Iaconis; G P Bodey; G Samonis
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

Review 8.  Beta-lactamase inhibitors from laboratory to clinic.

Authors:  K Bush
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

9.  Use of a predictor panel to evaluate susceptibility test methods proposed for piperacillin-tazobactam.

Authors:  P A Bradford; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

10.  Cefotaxime single-dose surgical prophylaxis in a prepaid group practice. Comparisons with other cephalosporins and ticarcillin/clavulanic acid.

Authors:  R N Jones; J M Slepack; W V Wojeski
Journal:  Drugs       Date:  1988       Impact factor: 9.546
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.